SEQUENCE LISTING

<110> GENZYME CORPORATION

<120> METHODS FOR TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST

<130> 558276: SA9-162PC

<140>
<141>

<150> EP 14305670.3
<151> 2014-05-07

<150> 61/837,912
<151> 2013-06-21

<160> 8

<170> PatentIn version 3.5

<210> 1
<211> 124
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic HCVR polypeptide"

<400> 1

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Glu	Gln	Pro	Gly	Gly
1				5				10					15		
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Gly	Ser	Gly	Phe	Thr	Phe	Arg	Asp	Tyr
			20					25				30			
Ala	Met	Thr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Ser	Ser	Ile	Ser	Gly	Ser	Gly	Gly	Asn	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
	50					55					60				
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
65					70					75					80
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Lys	Asp	Arg	Leu	Ser	Ile	Thr	Ile	Arg	Pro	Arg	Tyr	Tyr	Gly	Leu
			100					105					110		
Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser				
		115					120								

<210> 2
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic LCVR polypeptide"

<400> 2
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30

Ile Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Ser Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Phe Tyr Tyr Cys Met Gln Ala
85 90 95

Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic HCDR1 peptide"

<400> 3
Gly Phe Thr Phe Arg Asp Tyr Ala
1 5

<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic HCDR2
peptide"

<400> 4
Ile Ser Gly Ser Gly Gly Asn Thr
1 5

<210> 5
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic HCDR3
peptide"

<400> 5
Ala Lys Asp Arg Leu Ser Ile Thr Ile Arg Pro Arg Tyr Tyr Gly Leu
1 5 10 15

Asp Val

<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic LCDR1
peptide"

<400> 6
Gln Ser Leu Leu Tyr Ser Ile Gly Tyr Asn Tyr
1 5 10

<210> 7
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic LCDR2
peptide"

<400> 7
Leu Gly Ser
1

<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic LCDR3
peptide"

<400> 8
Met Gln Ala Leu Gln Thr Pro Tyr Thr
1 5